Genes that can be implicated in hypertension in experimental animals are plausible candidates in the pathogenesis of human hypertension. A recent genome-wide search for quantitative-trait loci (QTL) in hypertensive rats revealed a strong correlation between the interleukin-6 (IL-6) locus on rat chromosome 4 and systolic, diastolic, and mean arterial pressure in this mammalian species. To investigate a possible association between genetic variations of the IL-6 gene and hypertension in humans, we identified two novel single-nucleotide sequence variations, a C/G substitution at −634 in the promoter region and a G/A substitution at 4391 in a 3 ′ non-coding portion of exon 5, and a previous reported sequence variant, an A/T variation in the composition of the A n T n tract around −447 in the promoter region ( Fishman D et al. J Clin Invest 1998; 102: 1369-1376, within a test population of 96 Japanese subjects. Allelic associations involving these variations were analyzed in 150 hypertensive and 143 normotensive Japanese women. The distribution of alleles of the three polymorphisms, as well as a dinucleotide repeat present at the IL-6 locus, was similar in the two groups. Therefore, the IL-6 gene appears to play a minimal role in the genetic etiology of essential hypertension in Japanese women.
Introduction
Essential hypertension, a major independent risk factor for stroke, myocardial infarction, and end-stage renal failure, affects 15-20% of the adult population in industrialized societies. 1 The recognition that genetic factors are involved in the pathogenesis of hypertension is derived from studies comparing the blood pressures of monozygotic and dizygotic twins, 2 from epidemiologic studies of familial aggregation of hypertension, 3 and from studies comparing blood pressures among biologic and adoptive siblings. 4 Some genetic variants, such as polymorphisms in the angiotensinogen 5, 6 and ␣-adducin 7, 8 genes, can increase the risk for hypertension, but the full spectrum of genes that contribute to this condition are poorly defined.
Genetic analyses of large cohorts of inbred model organisms such as laboratory mice and rats are valuable for dissecting the genetic contributors to complex traits, 9 because many progeny can be studied while ensuring genetic homogeneity. 1, 9, 10 Experimental crosses thus permit dissection of more complex genetic interactions than can be studied directly in human families. Genes that are implicated in hypertension in experimental animals, for example, can then be treated as plausible candidates for pathogenetic roles in human hypertension.
Pravenec et al 11 performed a genome-wide analysis of quantitative trait loci (QTL) using recombinant inbred strains of rats (HBX and BXH) derived from a spontaneously hypertensive rat strain and the normotensive Brown Norway rat. Their results suggested that regulators of blood pressure were present on rat chromosomes 2, 4, and 19; in particular, a marker at the interleukin-6 (IL-6) locus on rat chromosome 4 was strongly correlated with systolic, diastolic, and mean arterial pressure. In the present study, we isolated single-nucleotide sequence variations at the human IL-6 locus, and assessed a possible association between those variations and essential hypertension in Japanese women. We also investigated a distribution of alleles of the CA-repeat microsatellite polymorphism at the human IL-6 gene locus that we described previously 12 among hypertensive and normotensive populations. As for this CA-repeat polymorphism, we detected seven alleles ( from allele A0, 136 bp in size containing 19 CA repeats to allele A6, 124 bp in size containing 13 CA repeats), each allele differing by two bases.
Results
One hundred and fifty hypertensive subjects (mean age, 69.7 ± 2.5 years) and 143 normotensive subjects (mean age, 69.6 ± 3.1 years) were recruited from unrelated volunteers living in the Akita prefecture of Japan. The bodymass indices of 150 hypertensive subjects and 143 normotensive subjects were 24.5 ± 3.6 and 23.0 ± 3.2 kg/m 2 respectively. Hypertensive subjects were diagnosed on the following criteria: (a) use of antihypertensive medications; and/or (b) systolic blood pressure higher than 159 mm Hg and/or diastolic blood pressure higher than 94 mm Hg. In hypertensive subjects, both observed systolic (156 ± 22.9 mm Hg) and diastolic (84 ± 10.9 mm Hg) blood pressures were higher than in normotensive subjects (132 ± 16.1 and 72 ± 8.3 mm Hg, respectively).
PCR-SSCP screening of 48 normotensive and 48 hypertensive subjects identified two novel single-nucleotide sequence variations, a C/G substitution at −634 in the promoter region and a G/A substitution at 4391 in a 3′ non-coding portion of exon 5, and a previous reported sequence variant, an A/T variation in the composition of the A n T n tract around −447 in the promoter region 13 ( Figure 1 ). These numbers correspond to the nucleotide number of the published sequence of Yasukawa et al. 14 The C/G substitution at −634 in the promoter region was genotyped in a format of BsrBI RFLP (Figure 1a ). Genotype frequencies of each variant in normotensive controls are shown in Table 1 ; genotype frequencies did not deviate from those predicted by Hardy-Weinberg law (data not shown).
All normotensive and hypertensive subjects were genotyped for the three molecular variants in the IL-6 gene ( Table 1) . We also investigated a distribution of alleles of the CA-repeat microsatellite polymorphism at the human IL-6 gene locus that we described previously 12 among hypertensive and normotensive populations. As for this CA-repeat polymorphism, we detected seven alleles (from allele A0, 136 bp in size containing 19 CA repeats, to allele A6, 124 bp in size containing 13 CA repeats), each allele differing by two bases. The results are shown in Table 2 . The distributions of alleles of all three types of molecular variants as well as those of the CA-repeat polymorphism were similar between the hypertensive and the normotensive group.
Discussion
IL-6 is a multifunctional cytokine that mediates pleiotropic functions in various types of cells. [15] [16] [17] It was originally described as a factor with a crucial role in the immune response, but subsequently IL-6 was also implicated in the inflammatory process, 18 viral infection, 19 autoimmunity, 20 development, 21 malignant cell growth, 17 and bone metabolism. 22 However, the possible role of IL-6 in the regulation of blood pressure and sodium-water balance has not been investigated extensively.
A genome-wide QTL analysis undertaken in another laboratory, using 500 genetic markers to genotype recombinant inbred strains of rats (HBX and BXH) derived from a spontaneously hypertensive strain and a normotensive strain, 11 indicated the presence of blood-pressure regulatory loci on rat chromosomes 2, 4, and 19. The IL-6 marker on chromosome 4 showed the strongest correlation with mean arterial pressure. Although the correlation between the IL-6 gene and hypertension in the rat crosses could reflect a general biological phenomenon, the etiology of hypertension may be quite different in rats and humans.
In the present study we screened all exons and exon/intron junctions of the human IL-6 gene, as well as 1 kb of the promoter region, by PCR-SSCP analysis of DNAs from our Japanese population sample. We identified three single-nucleotide sequence substitutions, two in the promotor region and one in the 3′-noncoding region. Two of them, a C/G substitution at -634 in the promoter region and a G/A substitution at 4391 in a 3′ noncoding portion of exon 5, are novel polymorphisms in the IL-6 gene. An A/T variation in the composition of the A n T n tract around −447 in the promoter region was already reported by Fishman et al. 13 Another IL-6 polymorphism, a G/C substitution at position −174 which Fishman et al 13 had associated with systemic-onset juvenile chronic arthritis in Caucasians, was not observed in our population. We had previously described a polymorphic dinucleotide (CA) microsatellite at the IL-6 locus. 12 We evaluated our panel of Japanese women for poss- ible association between essential hypertension and any of the four polymorphisms of the IL-6 gene, but found no significant correlations. The negative results could be explained in a number of ways. First, the etiology of hypertension may be quite different between rats and humans. The effect of a QTL allele may change, or even disappear, in a different genetic background, because of epistatic effects of other genes and/or differences among modifier genes that affect single-gene traits. We have been focusing on genetic epidemiology of common genetic variations in Japanese women. This research orientation led us to investigate the correlation between hypertension and DNA polymorphisms at IL-6 loci, specifically among Japanese women. Difference of sexes of study populations may be relevant to the different outcome between animal and human studies, ie both sexes were included in animal studies whereas only females were studied in the present study. Second, it is possible that genetic variations at the IL-6 marker in inbred rats might have reflected mutation of a nearby gene. Third, the contribution of IL-6 variation to human hypertension may be so small that our study simply lacked the power to detect it. Essential hypertension in humans appears to be a heterogeneous disease rather than a single disease entity, as judged from its complex segregation pattern. It is often the case in common polygenic diseases that genetic heterogeneity masks an association otherwise apparent between the phenotype and the genotype. Finally, a true mutation for human hypertension may be present in or around the IL-6 gene. More powerful genetic methods such as affected-sib pair analysis or family-linkage studies, and/or population studies in different ethnic backgrounds, will be necessary to clarify this issue.
Materials and methods

Subjects
We recruited 150 hypertensive subjects and 143 normotensive subjects from unrelated volunteers living in the Akita prefecture of Japan. Medical histories were determined by a standard questionnaire, which included inquiry into use of antihypertensive medications. Height and weight were recorded and body-mass index, defined as weight divided by height squared (kg/m 2 ), was calculated for each participant. Blood pressure was measured twice, with the subjects seated after resting. The criteria for diagnosis of essential hypertension included: (a) use of antihypertensive medications; and/or (b) systolic blood pressure higher than 159 mm Hg and/or diastolic blood pressure higher than 94 mm Hg. Patients with diabetes mellitus, renal failure, or secondary forms of hypertension had been excluded by the medical records. Samples of peripheral blood were obtained with informed consent and DNA was extracted from the buffy layer.
Screening for molecular variants in the IL-6 gene A total of 48 normotensive and 48 hypertensive subjects were initially screened for molecular variants in the IL-6 gene. PCR-SSCP procedure was performed to identify molecular variants at or around each exon and in the promoter region of the IL-6 gene. The primer sets for the PCR-SSCP procedure, which were designed from the human IL-6 gene sequence, 14 are present in Table 3 . PCR was performed in a volume of 10 l containing 20 ng genomic DNA, 10 mm Tris HCl (pH 8.4), 50 mm KCl, 1.5 mm MgCl 2 , 0.01% of gelatin, 200 m dNTPs, 2.5 pmol of a [ 32 P] end-labeled forward primer and a non-labeled reverse primer, and 0.25 units of Taq polymerase. Cycle conditions were 94°C for 4 min, then 35 cycles of 94°C for 30 s, 58°C for 30 s, and 72°C for 30 s, with a final extension step of 5 min at 72°C in a Gene Amp PCR9600 System (Perkin Elmer Cetus, CA, USA). Each PCR product was mixed with 10 l of loading buffer (95% formamide, 20 mm EDTA, 0.05% bromphenol blue, and 0.05% xylene cyanol), heated at 94°C for 5 min, rapidly cooled on ice, and applied to a 5% polyacrylamide gel containing 5% glycerol in 0.5× TBE buffer. Electrophoresis was performed under two different conditions to improve Table 3 Sequences of primers for the PCR-SSCP analysis of IL-6 gene
Name of primers
Nucleotide sequence of primers (forward/reverse) IL-6 promoter-A 5′-CTCAATGACGACCTAAGCTG-3′/5′-GCCTCAGACATCTCCAGTC-3′ IL-6 promoter-B 5′-ACTCTTTGTCAAGACATGCC-3′/5′-TGGGGCTGATTGGAAACCTT-3′ IL-6 promoter-C 5′-TCAGTTCAGAACATCTTTGGTT-3′/5′-ATGTCTTGACAAAGAGT-3′ IL-6 promoter-D 5′-CTTCTTCATAATCCAGGCTTG-3′/5′-AAAGCTGAAGTCATGCACGAAG-3′ IL-6 promoter-E 5′-GAGACGCCTTGAAGTAACTG-3′/5′-AACCAAAGATGTTCTGAACTGA-3′ IL-6 exon 1 5′-TATTAGAGTCTCAACCCCCAA-3′/5′-CTCGACCGGCTGGCAGTT-3′ IL-6 intron 1 5′-GCTATGAACTCCTTCTCCAC-3′/5′-AGAAGGCAACTGGACCGAAG-3′ IL-6 exon 2-A 5′-GTGCTGTCAGCTCACCCC-3′/5′-CTGCGAGGATGTACCGAATT-3′ IL-6 exon 2-B 5′-CCCAGGAGAAGATTCCAAAG-3′/5′-AAAGACCTCCTAATGCAGGC-3′ IL-6 exon 3-A 5′-TGGTGTTTGTTTTAGGGACAC-3′/5′-GGAGAAGTTTTGCCTAAGGAA-3′ IL-6 exon 4-A 5′-GGCGATAACCAATTTTCCCAC-3′/5′-CTGTCTTTGAGCCTGTCTTC-3′ IL-6 exon 5-A 5′-ATTTATTCAACATTTAAACAATCCT-3′/5′-CCGAAGAGCCCTCAGGCT-3′ IL-6 exon 5-B 5′-CTGCGCAGCTTTAAGGAGTT-3′/5′-TAGTGTCCTAACGCTCATACT-3′ IL-6 exon 5-C 5′-GGCACAGAACTTATGTTGTTC-3′/5′-CTGCATAGCCACTTTCCATTA3′5′-−634
GAGACGCCTTGAAGTAACTG-3′/5′-AACCAAAGATGTTCTGAACTGA-3′ A n T n at −447 5′-GAGACGCCTTGAAGTAACTG-3′/5′-AACCAAAGATGTTCTGAACTGA-3′ +4391 5′-GGCACAGAACTTATGTTGTTC-3′/5′-CTGCATAGCCACTTTCCATTA-3′
resolution for detecting different types of SSCP variants: 150 V for 16 h at room temperature, and 240 V for 16 h at 4°C. Gels were dried and autoradiographed with intensifying screens. Variant bands that presented mobility shifts with respect to wild-type were sequenced as described by Hata et al 23 with some modifications. In brief, each aberrant band was excised from the dried gel, suspended in 100 l of H 2 O, and incubated at 95°C for 5 min. A 5-l aliquot was subjected to enzymatic amplification in a 50-l reaction volume, with specific primers for each segment. PCR products were purified using the QIAquick PCR purification kit (Qiagen, Japan, Tokyo). Nucleotide sequences of PCR fragments were determined by Dye-Terminator cycle sequencing using Perkin-Elmer 377 ABI Prism instruments (Perkin Elmer Cetus).
Genotyping for molecular variants in the IL-6 gene
The A/T variation in the composition of the A n T n tract around −447 in the promoter region and the G/A substitution at 4391 in the 3′ non-coding region of exon 5 of the IL-6 gene were genotyped by the PCR-SSCP method in all participants. Primers for those PCR amplifications are shown in the Table 3 . The C/G substitution at −634 in the promoter region of the IL-6 gene was genotyped in a format of BsrBI restriction fragment-length polymorphism (RFLP) after amplification using PCR primers shown in Table 3 . The PCR products were digested with BsrBI and separated in 2% agarose gels. Procedures for genotyping a CA-repeat polymorphism at the IL-6 locus were described previously.
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Statistical analysis
Chi-square analysis was used to test for deviation of genotype frequencies from Hardy-Weinberg expectations, and also to test for differences between hypertensive and normotensive subjects in frequencies of alleles and genotypes.
